Deals > All

Europe & Israel North America Canada United States

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in North America, Europe and Israel or involving organisations from these countries.

Total search results: 6557 | Ordered by Date (descending)
1 2 3 ... 64 65 66

Deal: Collaboration or Financing	Date
Kate Therapeutics–Novartis: investment, 202411 acquisition up to $1.1b incl upfront cash payment + milestones by Novartis	2024-11-21
Pep2Tango Therapeutics–Versant Venures: investment, 202411 investment round €na with Versant Ventures	2024-11-21
Evotec–Halozyme: investment, 202411 acquisition €2b unsolicited + non-binding cash offer at €11/share refused + withdrawn NOT REALISED	2024-11-14
Biotheus–BioNTech: investment, 202411– acquisition 100% for $800m upfront mostly in cash + few ADSs plus $150m milestones	2024-11-13
Centogene–Charme Capital Partners: investment, 202411– acquisition €8.7m of sole operating subsidiary Centogene GmbH by affiliate of Charme Capital	2024-11-13
Alentis Therapeutics–Avego Bioscience Capital: investment, 202411 financing round Series D totalling $181.4m incl new + co-investor Avego BC	2024-11-12
Alentis Therapeutics–Catalio Capital: investment, 202411 financing round Series D totalling $181.4m incl new + co-investor Catalio Capital	2024-11-12
Alentis Therapeutics–Frazier: investment, 202411 financing round Series D totalling $181.4m incl new + co-investor Frazier Life Sciences	2024-11-12
Alentis Therapeutics–Longitude Capital: investment, 202411 financing round Series D totalling $181.4m incl new + co-investor Longitude Capital	2024-11-12
Alentis Therapeutics–OrbiMed: investment, 202411 financing round Series D totalling $181.4m incl lead investor OrbiMed	2024-11-12
Alentis Therapeutics–Piper Heartland Healthcare Capital: investment, 202411 financing round Series D totalling $181.4m incl new + co-investor PHHC	2024-11-12
Alentis Therapeutics–RA Capital: investment, 202411 financing round Series D totalling $181.4m incl existing + co-investor RA Capital Management	2024-11-12
Alentis Therapeutics–SEVERAL: investment, 202411 financing round Series D $181.4m led by OrbiMed with co-leads Novo Holdings + Jeito Capital	2024-11-12
Mainz Biomed–Thermo Fisher: colorectal cancer screening test, 202411– collab developm + commercialisation assays for mRNA-based CRC screening tests	2024-11-12
Pi Health–Bertelsmann: investment, <=202411 investment by new investor Bertelsmann Investments	2024-11-07
PrognomiQ–aMoon: investment, 202411 financing round Series D totalling $34m incl existing + co-investor aMoon	2024-11-05
PrognomiQ–Bruker: investment, 202411 financing round Series D totalling $34m incl existing + co-investor Bruker	2024-11-05
PrognomiQ–Catalio Capital: investment, 202411 financing round Series D totalling $34m incl existing + co-investor Catalio Capital Management	2024-11-05
PrognomiQ–Invus Group: investment, 202411 financing round Series D totalling $34m incl existing + co-investor Invus	2024-11-05
PrognomiQ–OTHER: investment, 202411 financing round Series D totalling $34m incl new large strategic diagnostics investor	2024-11-05
PrognomiQ–Seer: investment, 202411 financing round Series D totalling $34m incl existing + lead investor Seer Inc	2024-11-05
PrognomiQ–SEVERAL: investment, 202411 financing round Series D $34m led by Seer Inc	2024-11-05
Nuuron–SEVERAL: investment, 202410 seed financing round €3.5m led by HTGF	2024-10-31
Aignostics–Berlin (govt): investment, 202410 financing round Series B totalling $34m incl existing + co-investor VC Fonds Technologie	2024-10-29
Aignostics–Boehringer: investment, 202410 financing round Series B totalling $34m incl existing + co-investor BIVF	2024-10-29
Aignostics–Carma Fund: investment, 202410 financing round Series B totalling $34m incl existing + co-investor Carma Fund	2024-10-29
Aignostics–High-Tech Gründerfonds: investment, 202410 financing round Series B totalling $34m incl existing + co-investor HTGF	2024-10-29
Aignostics–Mayo Clinic: AI-based diagnostics, 202410 collab developm foundation models for digital pathology	2024-10-29
Aignostics–Mayo Clinic: investment, 202410 financing round Series B totalling $34m incl co-investor Mayo Clinic	2024-10-29
Aignostics–SEVERAL: investment, 202410 financing round Series B $34m led by Athos	2024-10-29
Aignostics–Strüngmann Group: investment, 202410 financing round Series B totalling $34m incl lead investor Athos	2024-10-29
Aignostics–Wellington Partners: investment, 202410 financing round Series B totalling $34m incl existing + co-investor Wellington Partners	2024-10-29
Aliada Therapeutics–AbbVie: investment, 202410– acquisition 100% for $1.4b in cash by AbbVie	2024-10-28
Kivu Bioscience–BioGeneration Ventures: investment, 202410 financing round Series A totalling $92m incl existing + co-investor BGV	2024-10-28
Kivu Bioscience–Gimv: investment, 202410 financing round Series A totalling $92m incl new + co-investor Gimv	2024-10-28
Kivu Bioscience–Lonza: ADC technology, 202410 existent use of GlycoConnect platform fo Synaffix by Kivu Bioscience	2024-10-28
Kivu Bioscience–Merck (DE): investment, 202410 financing round Series A totalling $92m incl existing + co-investor M Ventures	2024-10-28
Kivu Bioscience–Netherlands (govt): investment, 202410 financing round Series A totalling $92m incl existing + co-investor BOM	2024-10-28
Kivu Bioscience–Novo Group: investment, 202410 financing round Series A totalling $92m incl lead investor Novo Holdings	2024-10-28
Kivu Bioscience–Odlander Fredrikson: investment, 202410 financing round Series A totalling $92m incl new + co-investor HealthCap	2024-10-28
Kivu Bioscience–Red Tree Venture Capital: investment, 202410 financing round Series A totalling $92m incl new + co-investor Red Tree Venture Capital	2024-10-28
Kivu Bioscience–SEVERAL: investment, 202410 financing round Series A $92m led by Novo Holdings	2024-10-28
Nuclera–SEVERAL: investment, 202410 financing round $75m led by Elevage Medical Technologies (Patient Square Capital)	2024-10-16
Antiverse–SEVERAL: investment, 202410 seed financing round 2nd extension £3.5m led by i&i Bio + Kadmos Capital	2024-10-15
Invios–SEVERAL: investment, 202410 financing round Series A €8.2m incl existing investors + Ligand Pharmaceuticals	2024-10-15
Immatics–SEVERAL: investment, 202410– proposed public offering $150m	2024-10-10
Insitro–Lilly: drug delivery technology, 202410– two license option agreem to use GalNAc technology for two siRNA molecules of Insitro	2024-10-09
Insitro–Lilly: therapeutic antibody, 202410– collab r+d Ab for novel target for metabolic disease	2024-10-09
Purespring Therapeutics–ICR: public relations, 202410 service existent ICR Consilium is media contact	2024-10-09
Purespring Therapeutics–SEVERAL: investment, 202410 financing round Series B £80m led by Sofinnova Partners	2024-10-09
Bayer–Moma Therapeutics: drug discovery, 202410– collab + excl license option €na using KNOMTIC platform to discover small-molecule cancer drugs	2024-10-08
City Therapeutics–SEVERAL: investment, 202410 financing round Series A $135m led by ARCH Venture Partners	2024-10-08
Danaher–CrestOptics: spinning disk microscopy, 202410– collab integration of Cicero spinning disk unit into Thunder Imager of Leica Microsystems	2024-10-07
Enara Bio–Pfizer: investment, 202410 financing round Series B totalling $32.5m incl new + co-lead investor Pfizer Ventures	2024-10-03
Enara Bio–RA Capital: investment, 202410 financing round Series B totalling $32.5m incl existing + co-investor RA Capital	2024-10-03
Enara Bio–Samsara BioCapital: investment, 202410 financing round Series B totalling $32.5m incl existing + co-investor Samsara BioCapital	2024-10-03
Enara Bio–SEVERAL: investment, 202410 financing round Series B $32.5m co-led by new investors Pfizer Ventures + M Ventures	2024-10-03
Dynamic Biosensors–Bruker: investment, 202410 acquisition €na of Dynamic Biosensors GmbH + integration in Bruker Biosensors business	2024-10-02
Roche–Regor: CDK inhibitors, 202409– acquisition $850m cash upfront + milestones of portfolio of CDK inhibitors by Genentech from Regor	2024-09-30
Mirai Bio–Flagship Pioneering: investment, 202409 Mirai Bio emerges with initial $50m commitment from founding investor Flagship Pioneering	2024-09-26
Resonac–Altaris: investment, 202409– acquisition 100% of Minaris Regenerative Medicine Subsidiaries of Resonac by Altaris LLC	2024-09-26
Constructive Biology–SEVERAL: investment, 202409 financing round Series A first closing $58m led by Ahren + OMX Ventures + Paladin Capital	2024-09-24
Roivant–Organon: investment, 202409– acquisition of Dermavant Sciences by Organon $175m upfront + $1.025b milestones plus royalties incl product Vtama	2024-09-18
ImmunOs Therapeutics–BioMedPartners: investment, 202409 financing round Series C totalling $11m incl existing + co-lead investor BioMed Partners	2024-09-17
ImmunOs Therapeutics–Double Point Ventures: investment, 202409 financing round Series C totalling $11m incl new + co-investor Double Point Ventures	2024-09-17
ImmunOs Therapeutics–Mission BioCapital: investment, 202409 financing round Series C totalling $11m incl existing + co-lead investor Mission BC	2024-09-17
ImmunOs Therapeutics–Pfizer: investment, 202409 financing round Series C totalling $11m incl existing + co-lead investor Pfizer Ventures	2024-09-17
ImmunOs Therapeutics–SEVERAL: investment, 202409 financing round Series C $11m led by Gimv + Pfizer Ventures ü+ Mission BioCapital + BioMedPartners	2024-09-17
Trials24–Subject Well: investment, 202409 acquisition of Trials24 by SubjectWell backed by PE firm WindRose Health	2024-09-17
Cell Signaling Technology–e-Blot Life Science: imaging system, 202409– distribution of Touch Imager system by Bioké in 12 European countries	2024-09-16
Abolis Biotechnologies–Liberset: investment, 202409 financing round totalling €35m incl investor Liberset	2024-09-12
Abolis Biotechnologies–SEVERAL: investment, 202409 financing round €35m with BOLD L’Oréal VC Fund + Evonik Venture Capital et al	2024-09-12
Inflammatix–D1 Capital: investment, 202409 financing round Series E totalling $57m incl co-investor D1 Capital Partners	2024-09-12
Inflammatix–Iberis Capital: investment, 202409 financing round Series E totalling $57m incl co-investor Iberis Capital	2024-09-12
Inflammatix–Khosla Ventures: investment, 202409 financing round Series E totalling $57m incl co-lead investor Khosla Ventures	2024-09-12
Inflammatix–Northpond Ventures: investment, 202409 financing round Series E totalling $57m incl co-investor Northpond Ventures	2024-09-12
Inflammatix–OSF Healthcare: investment, 202409 financing round Series E totalling $57m incl co-investor OSF Healthcare	2024-09-12
Inflammatix–RAW Ventures: investment, 202409 financing round Series E totalling $57m incl co-investor RAW Ventures	2024-09-12
Inflammatix–SEVERAL: investment, 202409 financing round Series E $57m led by Khosla Ventures + Think.Health	2024-09-12
Inflammatix–Think.Health: investment, 202409 financing round Series E totalling $57m incl co-lead investor Think.Health	2024-09-12
Inflammatix–Vesalius Biocapital: investment, 202409 financing round Series E totalling $57m incl co-investor Vesalius Biocapital	2024-09-12
Novameat–SEVERAL: investment, 202409 financing round Series A €17.4m led by Sofinnova Partners + Forbion BioEconomy Fund	2024-09-12
Novameat–Unovis Asset Management: investment, 202409 financing round Series A totalling €17.4m incl existing + co-investor Unovis AM	2024-09-12
Organon–Bao Pharmaceutical: long-acting FSH, 202409– license + supply agreem for SJ02 in Mainland China $12m upfront + milestones	2024-09-12
Solasta Bio–SEVERAL: investment, 202409 financing round Series A $14m led by Forbion BioEconomy Fund	2024-09-11
NanoSyrinx–Lilly: investment, 202409 financing round totalling £10m incl new + co-investor Eli Lilly	2024-09-10
NanoSyrinx–SEVERAL: investment, 202409 financing round £10m co-led by BGF + Octopus Ventures + M Ventures	2024-09-10
NanoSyrinx–Zyme Communications: public relations, 202409 service existent by Zyme	2024-09-10
Vaxcyte–SEVERAL: investment, 202409 public offering $1.3b+$195m with 12.62m shares + pre-funded warrants + 1.9m shares common stock	2024-09-06
Immunocore–Danaher: data management software, 202409– supply Genedata SDMS for discovery of TCR therapeutics	2024-09-05
eGenesis–Bayer: investment, 202409 financing round Series D totalling $191m incl existing + co-investor Leaps by Bayer	2024-09-04
eGenesis–Fresenius: investment, 202409 financing round Series D totalling $191m incl existing + co-investor FMCV	2024-09-04
eGenesis–Lux Capital: investment, 202409 financing round Series D totalling $191m incl lead investor Lux Capital	2024-09-04
eGenesis–SEVERAL: investment, 202409 financing round Series D $191m from existing + new investors led by Lux Capital	2024-09-04
Mainz Biomed–Liquid Biosciences: AI-based cancer diagnostics, 202409– collab expansion using EMERGE platform to advance PancAlert screening test	2024-09-04
Vignette Bio–EpimAb Biotherapeutics: bispecific antibody, 202409– license ww outside China $60m upfront cash+equity + $575m milestones + royalties	2024-09-04
Vignette Bio–EpimAb Biotherapeutics: investment, 202409 equity investment as part of $60m upfront payment in cash + equity in license deal	2024-09-04
Vignette Bio–Foresite Capital: investment, <202409 seed financing round incl lead investor Foresite Capital	2024-09-04
Vignette Bio–Mirae Asset: investment, <202409 seed financing round incl co-investor Mirae Asset Capital Life Science	2024-09-04
Vignette Bio–Qiming: investment, <202409 seed financing round incl co-investor Qiming Venture Parnters USA	2024-09-04

1 2 3 ... 64 65 66

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

» top